Search

BioNTech SE ADR

Slēgts

SektorsVeselības aprūpe

92.98 0.85

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

89.88

Max

93.19

Galvenie mērījumi

By Trading Economics

Ienākumi

-294M

-834M

Pārdošana

-13M

107M

EPS

-3.03

Peļņas marža

-777.273

Darbinieki

7,807

EBITDA

-32M

-482M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+33.83% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 3. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-17M

23B

Iepriekšējā atvēršanas cena

92.13

Iepriekšējā slēgšanas cena

92.98

Ziņu noskaņojums

By Acuity

19%

81%

51 / 340 Rangs Healthcare

BioNTech SE ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. aug. 19:26 UTC

BioNTech SE shares are higher today, continuing an upward trend since Thursday. This movement occurs despite concerns over declining U.S. retail sales data.

2026. g. 13. aug. 19:21 UTC

News

BioNTech SE shares are lower as analysts adjust price targets following a significant second-quarter revenue decline and a net loss of €820.8 million.

2026. g. 12. aug. 19:26 UTC

Correlated Moves

BioNTech SE's shares are higher today, supported by a significant rise in Moderna Inc. amid optimistic market sentiment following recent inflation data.

2026. g. 11. aug. 20:06 UTC

BioNTech SE shares are near unchanged amid a flat market performance. The stock remains above its 20-day moving average and near the upper end of its one-month range.

2026. g. 10. aug. 21:01 UTC

BioNTech SE shares are higher in after-market trading, showing stability despite broader market conditions and weaker-than-expected job growth data.

2026. g. 7. aug. 19:56 UTC

News
Correlated Moves

BioNTech SE is trading higher, likely influenced by Moderna's significant gains. The stock remains above its 20-day moving average despite recent revenue declines.

2026. g. 6. aug. 19:51 UTC

News
Correlated Moves

BioNTech SE shares are lower amid negative sentiment in the Biotechnology sector, following a revenue decline and CEO transition announcement.

2026. g. 5. aug. 19:32 UTC

News

BioNTech SE shares are higher today after Citigroup maintained its Buy rating, lowering its price target to $125 while Evercore ISI kept its Outperform rating at $130.

2026. g. 4. aug. 20:03 UTC

News
Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

2026. g. 3. aug. 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

2026. g. 31. jūl. 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

2026. g. 29. jūl. 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

2026. g. 28. jūl. 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

2026. g. 27. jūl. 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

2026. g. 24. jūl. 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

2026. g. 22. jūl. 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

2026. g. 21. jūl. 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

2026. g. 20. jūl. 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Salīdzinājums

Cenas izmaiņa

BioNTech SE ADR Prognoze

Cenas mērķis

By TipRanks

33.83% augšup

Prognoze 12 mēnešiem

Vidējais 124.58 USD  33.83%

Augstākais 142 USD

Zemākais 92 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioNTech SE ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

10

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

51 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
help-icon Live chat